NCT05983575
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 29 words Show 4 more changesShow less
- Primary completion date changed from estimate of Jan 31, 2026 to Jun 30, 2026
- Study completion pushed from Jul 31, 2026 to Mar 31, 2027
- Site details revised at 1 of 19 sites
- Publications: details revised at 2 of 2 entries
- Study Identification, Study Statusv7
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 19 of 19 sites
- Minor Study sites: 18 to 19v5
- Minor Study sites: 17 to 18v4
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 12 to 17
- Start date changed from estimate of Aug 2023 to Oct 31, 2023
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Aug 1, 2023 to Aug 2023
- Site details revised at 12 of 12 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Changes in ADAS-J-cog-14 scores from baseline to Week 72
Timeframe: Performed at Week 72
Secondary (13)
Changes in ADAS-J-cog-14 scores from baseline to Week 24 and 48
Changes in CDR-SB from baseline to Week 48 and 72
Changes in NPIQ-J scores from baseline to Week 24, 48 and 72
Changes in J-ZBI scores from baseline to Week 24, 48 and 72
Changes in WMS-R scores from baseline to Week 24, 48 and 72
Show 8 moreShow less
Changes in MMSE-J scores from baseline to Week 24, 48 and 72
Changes in FAQ scores from baseline to Week 24, 48 and 72
Changes in EQ-5D-5L scores from baseline to Week 24, 48 and 72
Changes in ABC Dementia scale scores from baseline to Week 24, 48 and 72
Changes in each 14 item of ADAS-J-cog-14 score from baseline to Week 24, 48 and 72
Prevalence of responders at Week 24, 48, and 72 defined as those with no deterioration or even improvement in ADAS-J-cog-14 scores
Transition rate from MCI due to AD to AD at Week 72
Termination due to aggravation of dementia symptoms
Arms and interventions
LIPUS-BrainExperimental
PlaceboPlacebo comparator
Devices: LIPUS-Brain, Placebo
Sites
19 sites in 1 country